Legislation Includes Measures to Increase Patient and Expert Participation in FDA Review of Rare Disease Drugs
Site Search
The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.
Preston W. Campbell, III, President and CEO to retire; Michael P. Boyle, MD, appointed as successor effective January 2020.
The Cystic Fibrosis Foundation has announced the recipients of its first annual Impact Grants.
Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab
Barisic will transition from current role as Chief Financial and Administrative Officer in January 2023
Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation